Investor Relations

Overview

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta™ (lefamulin), recently approved by the FDA for both Oral and IV use, and CONTEPO (fosfomycin) for injection. We resubmitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs), including acute pyelonephritis (AP). The FDA has assigned a PDUFA date of June 19,2020 for CONTEPO. Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.

Events & Presentations

Upcoming

Wednesday August 12, 2020 2:20 PM EDT
Wedbush PacGrow Healthcare Virtual Conference

Prior

Thursday June 4, 2020 1:00 PM EDT
Jefferies Virtual Healthcare Conference

Wednesday May 13, 2020 11:00 AM EDT
BofA Securities 2020 Virtual Health Care Conference

SEC Filings

Filing date Description Form Filing Group View

Report of unscheduled material events or corporate event

8-K
Current Reports
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Quarterly report which provides a continuing view of a company's financial position

10-Q
Quarterly Filings
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Statement of changes in beneficial ownership of securities

4
3,4,5
View HTML

Investor Contacts

E-mail: IR@nabriva.com